Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial

BACKGROUND: This study aimed to evaluate the efficacy and safety of RAY1216, a novel inhibitor of 3-chymotrypsin-like cysteine protease (3CLpro), in adults with coronavirus disease 2019 (COVID-19). METHODS: This phase 2, single centre, randomised, double-blind, placebo-controlled trial included hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bei, Li, Hai-jun, Cai, Mi-mi, Lin, Zhao-xin, Ou, Xia-fei, Wu, Shu-hua, Cai, Rui-huan, Wei, Ying-na, Yang, Fei, Zhu, Ya-min, Yang, Zi-feng, Zhong, Nan-shan, Lin, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484968/
https://www.ncbi.nlm.nih.gov/pubmed/37692076
http://dx.doi.org/10.1016/j.eclinm.2023.102189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484968/
https://www.ncbi.nlm.nih.gov/pubmed/37692076
http://dx.doi.org/10.1016/j.eclinm.2023.102189

Ejemplares similares